New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®

We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac disease. Both assays specifically quantify levels of zonulin with no cross-reactivity to haptoglobin 1 or 2. These new zonulin ELISAs expand our current gastrointestinal assay panel to investigate bile acids, calprotectin, alpha-1 antitrypsin, lysozyme, secretory IgA and pancreatic elastase.

We will also introduce our IBD therapeutic drug monitoring assay portfolio. Therapeutic drug monitoring of biologics and antibodies against biologics in IBD can provide significant information in determining the appropriate dose. Our therapeutic drug monitoring panel includes ELISAs for testing response to the commonly used biologics adalimumab, infliximab, golimumab, and vedolizumab. These ELISAs are Health Canada Licensed, however remain for Research Use Only in the United States.

When asked why the company chose to launch these products at Digestive Disease Week®, ALPCO President Sean Conley explained, “This meeting hosts physicians, researchers, and academics in the gastroenterology field who, like us, share the common goal of advancing research to help improve patient outcomes. As such, we felt this was the best arena for us to showcase new product offerings that can not only aid in gastroenterology research, but also eventually improve the quality of care that healthcare professionals can provide to their IBD patients.”

To learn more, visit us in booth 2211 at Digestive Disease Week®.


Digestive Disease Week® and DDW® are registered trademarks of the DDW LLC.